Salarius Pharmaceuticals, Inc. (SLRX)
NASDAQ: SLRX · Real-Time Price · USD
0.6851
+0.0140 (2.09%)
At close: Dec 19, 2025, 4:00 PM EST
0.6900
+0.0049 (0.72%)
After-hours: Dec 19, 2025, 7:24 PM EST
Salarius Pharmaceuticals Employees
Salarius Pharmaceuticals had 2 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,502,379
Market Cap
4.02M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | 0 | - |
| Dec 31, 2023 | 2 | -10 | -83.33% |
| Dec 31, 2022 | 12 | -4 | -25.00% |
| Dec 31, 2021 | 16 | 7 | 77.78% |
| Dec 31, 2020 | 9 | 1 | 12.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLRX News
- 1 day ago - Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewsWire
- 2 days ago - Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - GlobeNewsWire
- 19 days ago - Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewsWire
- 4 weeks ago - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewsWire
- 5 weeks ago - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewsWire
- 5 weeks ago - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - PRNewsWire
- 2 months ago - Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements - GlobeNewsWire
- 3 months ago - Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire